Journal of the European Academy of Dermatology and Venereology· 2018Q1
Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
- 1,178citations
- Q1SCImago
- 2018year
Short summary
New European guidelines offer a consensus-based approach to treating atopic eczema, emphasizing individualized care and basic barrier repair over highly standardized rules.
AI-generated from the title and abstract; the full text is not read.
Key points
- Treatment for atopic eczema should be individualized, not standardized.
- Basic therapy focuses on hydrating emollients and avoiding triggers.
- Topical corticosteroids are the primary treatment for flares and long-term control.
- Tacrolimus and pimecrolimus are preferred for sensitive skin areas and long-term use.
AI-generated from the title and abstract; the full text is not read.
Abstract
This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions. Management of AE must consider the individual clinical variability of the disease; highly standardized treatment rules are not recommended. Basic therapy is focused on treatment of disturbed barrier function by hydrating and lubricating topical treatment, besides further avoidance of specific and unspecific provocation factors. Topical anti-inflammatory treatment based on glucocorticosteroids and calcineurin inhibitors is used for flare management and for proactive therapy for long-term control. Topical corticosteroids remain the mainstay of therapy, whereas tacrolimus and pimecrolimus are preferred in sensitive skin areas and for long-term use. Topical phosphodiesterase inhibitors may be a treatment alternative when available. Adjuvant therapy includes UV irradiation, preferably with UVB 311 nm or UVA1. Pruritus is targeted with the majority of the recommended therapies, but some patients may need additional antipruritic therapy. Antimicrobial therapy, systemic anti-inflammatory treatment, immunotherapy, complementary medicine and educational intervention will be addressed in part II of the guideline.
The authors' abstract, as published at the source. Journal of the European Academy of Dermatology and Venereology, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Dermatology
DermatologyMedicine